{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:17:28Z","timestamp":1792790248736,"version":"4.5.0"},"reference-count":21,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"Curocell Inc"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:p>Purpose Anbalcabtagene autoleucel (anbal-cel) is a second-generation CD19-targeted chimeric antigen receptor T-cell therapy reducing T-cell exhaustion through programmed death-1 and T cell immunoreceptor with Ig and ITIM domains downregulation. We compared efficacy of anbal-cel with tisagenlecleucel (tisa-cel) in relapsed\/refractory diffuse large B-cell lymphoma using external control arm study design.Materials and Methods We performed a matching-adjusted indirect comparison (MAIC) using individual patient data from CRC01-01 (NCT#04836507) and aggregate data from JULIET trial (NCT#02445248). Primary outcomes were overall survival (OS) and progression-free survival (PFS), with corresponding hazard ratio (HR) and 95% confidence interval (CI) assessed using weighted Cox proportional hazard model. Secondary outcomes were objective response rate (ORR) and complete response rate (CRR), with corresponding odds ratio (OR) and 95% CI assessed using weighted logistic regression model.Results We included 79 patients in CRC01-01 and 115 in JULIET trial. In na\u00efve comparison, median OS was not reached (95% CI, 13.1 to not estimable) for anbal-cel versus 11.1 months (95% CI, 6.6 to 23.9) for tisa-cel, corresponding to HR of 0.54 (95% CI, 0.34 to 0.87). Median PFS was 5.5 months (95% CI, 4.2 to 16.2) versus 2.9 months (95% CI, 2.3 to 5.2) with HR of 0.73 (95% CI, 0.50 to 1.08). ORR was 73.4% versus 53.0% with OR of 2.45 (95% CI, 1.32 to 4.54), and CRR was 64.6% versus 39.1% with OR of 2.83 (95% CI, 1.56 to 5.13). After applying MAIC to balance prognostic factors between the groups, adjusted HRs or ORs were 0.47 (95% CI, 0.23 to 0.95) for OS, 0.59 (95% CI, 0.36 to 0.96) for PFS, 2.60 (95% CI, 1.04 to 6.52) for ORR, and 3.00 (95% CI, 1.30 to 6.92) for CRR.Conclusion Anbal-cel showed superior effectiveness over tisa-cel, with higher response rates and improved survival outcomes, even after accounting for imbalances in prognostic factors at trial enrollment.<\/jats:p>","DOI":"10.4143\/crt.2025.276","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T06:32:08Z","timestamp":1765780328000},"page":"945-953","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative Effectiveness of Anbalcabtagene Autoleucel versus Tisagenlecleucel in Patients with Relapsed\/Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9182-7625","authenticated-orcid":true,"given":"Hee-Jin","family":"Seo","sequence":"first","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8185-3906","authenticated-orcid":true,"given":"Woo Hyeon","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungyeon","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Won","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"},{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Korea"},{"name":"Department of Clinical Research Design and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7253-6515","authenticated-orcid":true,"given":"Ju Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea"},{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-0466","authenticated-orcid":true,"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","first-page":"1218","type":"journal-article","volume-title":"NCCN Guidelines(R) insights: B-cell lymphomas, version 5.2021","author":"Zelenetz","year":"2021"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.366","type":"journal-article"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010070","type":"journal-article"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31366-0","type":"journal-article"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30864-7","type":"journal-article"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00375-2","type":"journal-article"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0351","type":"journal-article"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020340","type":"journal-article"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004","type":"journal-article"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-022-00268-z","type":"journal-article"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01144-9","type":"journal-article"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000436","type":"journal-article"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation.v2012.1.402.3798516","type":"journal-article"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","type":"journal-article"},{"key":"ref15","first-page":"S558","type":"journal-article","volume-title":"Maicplus: an R package to support analysis and reporting of matching adjusted indirect treatment comparisons (MAIC) for HTA dossiers","author":"Chen","year":"2023"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00591-x","type":"journal-article"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00662-6","type":"journal-article"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01222-8","type":"journal-article"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-524108","type":"journal-article"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.09.004","type":"journal-article"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-887067","type":"journal-article"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-276.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.276","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-276.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:30:46Z","timestamp":1783931446000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.276","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2025-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}